Skin prick test reactivity to supplemental enzymes in cystic fibrosis and pancreatic insufficiency.
BACKGROUND
Patients with cystic fibrosis and pancreatic insufficiency take supplemental pancreatic enzymes of porcine or plant origin on a daily basis.


OBJECTIVE
The frequency of immediate skin prick hypersensitivity reactions to such enzymes and the correlations to gastrointestinal symptoms and nutritional status were assessed in a single center prospective descriptive study.


METHODS
Skin prick tests using five different freshly prepared porcine pancreatic enzyme preparations, one enzyme preparation of fungal origin, porcine meat and cat epithelia were performed in patients with cystic fibrosis and pancreatic insufficiency and in healthy control subjects.


RESULTS
Positive skin tests in the 48 patients with cystic fibrosis were no more frequent than in 21 control subjects. No correlations with the frequency of gastrointestinal symptoms, nutritional status and lung function were found.


CONCLUSIONS
Although immediate hypersensitivity reactions to pancreatic enzyme preparations in subjects with cystic fibrosis are not common, individuals with possible allergic reactions to supplemental enzymes should be identified by skin prick tests and in unclear cases by double-blind placebo-controlled provocation tests.
Griese
Matthias
M
Lung Research Group, Children's Hospital, Ludwig Maximilians University, Munich, Germany. matthias.griese@med.uni-muenchen.de
Dokupil
Kathi
K
Latzin
Philipp
P
D000293:Adolescent; D000328:Adult; D000818:Animals; D001985:Bronchial Provocation Tests / Q000379:methods; D016022:Case-Control Studies; D002648:Child; D002675:Child, Preschool; D003550:Cystic Fibrosis / Q000201:enzymology / Q000628:therapy*; D010188:Exocrine Pancreatic Insufficiency / Q000201:enzymology / Q000628:therapy*; D005260:Female; D005765:Gastrointestinal Agents / Q000009:adverse effects / Q000276:immunology* / Q000627:therapeutic use; D006801:Humans; D007159:Immunologic Tests / Q000379:methods; D008297:Male; D009752:Nutritional Status; D020799:Pancrelipase / Q000009:adverse effects / Q000276:immunology* / Q000627:therapeutic use; D011446:Prospective Studies; D012882:Skin Tests / Q000379:methods*; D013552:Swine
D005765:Gastrointestinal Agents; D020799:Pancrelipase